‘Trouble Is Opportunity’; Endo Fallout is Worth A Look
Long Ideas - It’s not easy to do, but buying when there’s blood in the streets is a way many have scored big on Wall Street. Take our … Continue Reading
Read NowLong Ideas
Acadia Financing Relieves Pressure and Sets the Stage for Progress
Long Ideas - Acadia Pharmaceuticals (NASDAQ:ACAD) announced on Wednesday morning a private equity financing to sell 19 million shares of common stock at $4.43 per share, plus warrants to purchase … Continue Reading
Read NowCADX To Receive $14.5M Or $0.15/Share In Non-Dilutive Funds
Long Ideas - Cadence Pharmaceuticals (NASDAQ:CADX) announced that it will terminate its option to acquire privately-held Incline Therapeutics in order for The Medicines Company (NASDAQ:MDCO) to buy Incline … Continue Reading
Read NowJapanese Amitiza Launch Provides Immediate Upside for SCMP
Long Ideas - Sucampo Pharmaceuticals (NASDAQ:SCMP) has announced that its commercialization partner for Japan, Abbot Labs (NYSE:ABT), recorded the first sale in the country of Sucampo’s prescription treatment … Continue Reading
Read NowPartnerships, Broad Pipeline Are Long-Term Boons for Isis Pharmaceuticals
Long Ideas - Biogen Idec (BIIB) and Isis Pharmaceuticals (ISIS) announced another partnership deal on Monday, the third in the last year, for the discovery and development of … Continue Reading
Read NowZIOPHARM: Key Oncology Catalyst Approaching
Long Ideas - The war against cancer has proven to be a difficult war to win. For decades, researchers and doctors have looked for ways to more effectively … Continue Reading
Read NowUpside in HALO; Roche Filing, Milestone Payment, and Data
Long Ideas - Halozyme Therapeutics (NASDAQ:HALO) announced on Saturday that its partner Roche (OTC: RHHBY) submitted its European application to market subcutaneous (SC) MabThera, also known as Rituxan. … Continue Reading
Read Now